What distinguishes the two types is the differing timing of these events and the relative impact, as illustrated by mutations in the TP53 tumor suppressor, which are found in nearly 70% of IBD-associated SBA patients [13]. The gene discussed is TP53; the disease is inflammatory bowel disease.